Submissions should be sent to email@example.com in Word format and contain all authors and affiliations.
Late-breaking abstracts will be only considered as Posters (PDF and video) and for short presentations in “poster walk sessions”.
General Rules for Submission
Only one paper or poster may be presented by the same author at the meeting, although a presenter may be coauthor of any number of papers. The material should not have been published or presented at any European meeting prior to the date of presentation. It is permissible, however, to have presented the material previously at a regional meeting and to have had it published in abstract form in a publication associated with one of these meetings.
Abstract submissions may only be made through the website. Support is available by contacting the ESDR Office (firstname.lastname@example.org)
All abstracts submitted to the ESDR meeting will be considered for oral presentation at the main ESDR meeting, except those marked for poster presentation by the author.
If your abstract is not selected for oral presentation at the main ESDR meeting, you may be invited to give an oral presentation at a satellite meeting of the 50th Annual ESDR Meeting. In this case you will be contacted directly by the organisers of the satellite meeting.
Abstracts will be published in the September 2021 issue of the Journal of Investigative Dermatology. Late-Breaking abstracts will not be published.
Submission Deadline – extended
Saturday 5 June 2021 – 17.00 CET
Friday 27 August 2021 – 17.00 CET
Abstract Submission – Detailed Instructions
Please complete the steps in the on-line abstract submission procedure on the ESDR abstract submission website adhering to the instructions given there. To submit the abstract text, you must copy your text into the form provided. Do not exceed 2300 characters (including spaces, authors and affiliations).
Abstracts must conform to the following standards:
Maximum of 10 co-authors.
Please indicate each co-author’s principal affiliation only.
DO NOT exceed 2300 characters including spaces (also including authors and affiliations). Overly long abstracts may be edited.
DO NOT use graphics or tables.
DO NOT use subheadings like “RESULTS, DISCUSSION” etc in your text. These will be deleted.
DO NOT number sections in your abstract.
DO NOT put author names or affiliations in the abstract text. This will help to ensure that your abstract is reviewed fairly.
DO NOT use capitals or underline for emphasis in the text. Use the standard Symbol font for Greek and math symbols.
DO NOT mention support of work by a research grant.
DO NOT include references. These will be deleted.
The title must be brief and indicate clearly the nature of the investigation. The title should be upper and lowercase letters. Abbreviations must not be used in the title.
Nonproprietary (generic) names should be given the first time a drug is mentioned in the body of the abstract and should be written in small letters. The first letter of a proprietary name is always capitalized, e.g., cyproheptadine (Periactin).
The abstract body should be organised as follows:
(a) a sentence describing the purpose of the study;
(b) a statement of experimental design or method used;
(c) a summary of results, presented in sufficient detail to support the conclusion; and
(d) a statement of conclusions reached.
It is not satisfactory to state “The results will be discussed…” or “Other data will be presented.”
Failure to follow these instructions will result in a low priority score and may cause disqualification of your abstract.).